Ben Butkus

At the AMP annual meeting this week, leadership briefed members on what to expect as its lawsuit challenging the FDA final rule on laboratory-developed test regulation unfolds.

The company beat analysts' estimates on the top and bottom lines with growth driven by increased testing volumes and improvements in average test selling price.

As demonstrated during the COVID-19 pandemic and in newer research, saliva holds promise as an alternative sample type for PCR-based infectious disease testing.

In a BioMérieux-sponsored symposium, economist Lord Jim O'Neill revisited a 2016 report on AMR while experts discussed the use of rapid testing tools such as those offered by the French company.

DeepUll showcased its UllCore platform and BSI Test, a one-hour multiplex PCR assay targeting 95 percent of sepsis-causing pathogens and multiple antibiotic resistance genes.

The partnership, announced last week just before ECCMID kicked off, is the first major foray for both companies into the sequencing-based infectious disease diagnostics market.

The company will launch 37 CE-IVD-marked assays this year, mostly for infectious diseases, for use on the QuantStudio 5 Dx and eventually QuantStudio 7 Pro Dx platforms.

The blood-based assay, called Actiphage, combines phage-induced lysis of infectious bacteria and molecular detection of bacterial DNA.

The prototype assay, presented at ECCMID in Lisbon, integrates sample preparation and RT-PCR to measure a six-mRNA host signature.

COVID-19 accelerated the growth of several product portfolios, but under CEO Thierry Bernard, the company is ready to put the pandemic behind it — mostly.